AUDIT, RESEARCH AND GUIDELINE UPDATE

Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS)

David Couper,1 Lisa M LaVange,1 MeiLan Han,2 R Graham Barr,3 Eugene Bleecker,4 Eric A Hoffman,5 Richard Kanner,6 Eric Kleerup,7 Fernando J Martinez,8 Prescott G Woodruff,9 Stephen Rennard10 for the SPIROMICS Research Group

ABSTRACT
Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) is a multicentre observational study of chronic obstructive pulmonary disease (COPD) designed to guide future development of therapies for COPD by providing robust criteria for subclassifying COPD participants into groups most likely to benefit from a given therapy during a clinical trial, and identifying biomarkers/phenotypes that can be used as intermediate outcomes to reliably predict clinical benefit during therapeutic trials. The goal is to enrol 3200 participants in four strata. Participants undergo a baseline visit and three annual follow-up examinations, with quarterly telephone calls. Adjudication of exacerbations and mortality will be undertaken.

INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a chronic, usually progressive, lung disease characterised by incompletely reversible airflow obstruction. Both the airways (obstructive bronchiolitis/ small airways disease) and the parenchyma (emphysema/parenchymal destruction) contribute to the airflow obstruction and ultimately dyspnoea. Additional processes such as mucous hypersecretion (chronic bronchitis) and exacerbations contribute to the overall impact of the disease. COPD is the third leading cause of death in the USA.

There are no proven medical therapies for COPD, other than supplemental oxygen and smoking cessation, which significantly reduce mortality. No pharmacological treatments have been shown to modify meaningfully the long-term decline in lung function. Complicating the therapeutic scenario is the fact that the disease is highly heterogeneous. Obstructive bronchiolitis and emphysema are clinically distinct histological entities, but individual patients with COPD may have either or both. Moreover, each can occur in an absence of spirometrically defined COPD and likely result from a number of mechanistic pathways. The recognition of COPD as a systemic disease that affects extra-pulmonary systems, including cardiovascular, sleep and muscle function, further complicates disease classification. Because of clinical and pathological heterogeneity, individual patient subtypes may benefit from unique therapeutic regimens. Identifying meaningful subpopulations of COPD patients is a key goal of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Additionally, the efficiency and cost of clinical trials could be improved considerably by validated intermediate endpoints.

OBJECTIVES OF SPIROMICS
SPIROMICS has two primary aims. Primary aim 1 is to identify homogeneous subgroups of patients with COPD for targeted enrolment in future therapeutic clinical trials. Primary aim 2 is intermediate endpoint discovery and validation. SPIROMICS will endeavour to identify intermediate outcome measures that predict long-term clinical endpoints of morbidity. There are also three secondary aims, involving cohort building, developing a COPD controlled vocabulary, and supporting ancillary studies.

Further details of the aims and other aspects of the study are provided in the online supplement.

STUDY DESIGN AND METHODS
SPIROMICS is a prospective cohort study that will enrol 3200 participants into four strata (non-smokers, smokers without airflow obstruction, mild/moderate COPD, and severe COPD) as shown in table 1.

Participants may be enrolled in concurrent observational studies, excluding the COPDGene Study, which will facilitate combined analyses between SPIROMICS and COPDGene. Subjects enrolled in
therapeutic clinical trials may enrol in SPIROMICS after the treatment is unmasked; those in SPIROMICS may be recruited into other interventional studies after SPIROMICS baseline values are obtained.

The Institutional Review Boards/Ethics Committees of all the cooperating institutions have approved the study protocols.

Inclusion and exclusion criteria
Participants must be 40–80 years of age at baseline, have a smoking history of ≤1 pack-year (stratum 1) or ≥20 pack-years (strata 2–4) and meet lung function criteria as specified in table 1. Major exclusion criteria are non-COPD obstructive lung disease or a history of diseases or treatments likely to interfere with interpretation of study tests, body mass index >40 kg/m² at baseline, hypersensitivity to or intolerance of the bronchodilators used in study assessments and diagnosis of unstable cardiovascular disease. Lung surgery and metal in the chest that may affect the chest CT interpretation is also exclusionary. Online supplementary table S1 contains the complete list of exclusion criteria.

Baseline and follow-up assessments
There are baseline (visit 1) and three annual in-person follow-up visits (visits 2–4). Participants also receive quarterly follow-up calls to assess health status and determine if an exacerbation has occurred. Visits 1, 2 and 4 include anthropometry, seated blood pressure, spirometry, 6 min walk test, biological specimen collection, and a series of questionnaires (see online supplementary table S2). Information is collected on medical history, respiratory exposures and current medications. Visit 3 omits specimen collection. Visits 1 and 2 include a thoracic CT scan at maximum inspiration and expiration.

Clinical outcomes, including hospitalisations and deaths, will be adjudicated centrally.

Imaging
Acquisition of state-of-the-art CT images is a key component in SPIROMICS for detailed phenotype identification (see online supplementary table S3). Two CT scans are performed, one at total lung capacity (TLC), and one at residual volume. The CT protocol for the TLC scan is identical to that used in other National Heart, Lung, and Blood Institute (NHLBI)-sponsored studies, including the Multi-ethnic Study of Atherosclerosis (MESA) Lung Study and the Severe Asthma Research Program (SARP), which will facilitate comparative papers across studies.

Biospecimen collection
Fasting blood and urine specimens are collected at visits 1, 2 and 4. Approximately 70 mL of blood is collected per visit, including plasma and serum. DNA will be extracted from blood collected at visit 1 and RNA from PAX-Gene tubes collected at visits 1 and 2. Urine is collected into aliquots with and without preservative. One ethylenediaminetetraacetic acid plasma specimen is assessed locally for complete blood, differential and platelet count. All other samples are sent to the SPIROMICS biospecimen repository. Additional blood and urine samples are collected from participants in the substudies. Induced sputum samples are collected at the baseline visit. Sputum is being processed using the ‘whole sputum’ method.

SUBSTUDIES AND ANCILLARY STUDIES
A substudy is a component of the protocol funded by the SPIROMICS contract and performed on a subset or the entire cohort. An ancillary study is one that contributes new data to SPIROMICS but whose aims are distinct from the parent study. Ancillary studies are not funded as part of the parent study. However, they must be approved by SPIROMICS to assure that the use of SPIROMICS resources are scientifically and practically justified and that the study does not interfere with the primary goals of SPIROMICS.

Three key substudies are the Repeatability and Replicate Substudy, in which 100 participants will have the entire baseline visit including the CT scanning repeated to quantify reliability and short-term within-person variability of study procedures and assay methods; (2) the Bronchoscopy Substudy, in which 300 participants will undergo bronchoscopy with bronchoalveolar lavage, epithelial brushings and bronchial biopsies; and (3) the Exacerbation Substudy, in which up to 400 participants will be followed prospectively and biological samples and clinical information will be collected at the time of an acute exacerbation.

STUDY ORGANISATION
SPIROMICS has six core clinical centres, with subsites and satellite clinics, and several central agencies. These are the NHLBI Project Office, a Genomics and Informatics Center (which functions as the data and statistical coordinating centre and includes the biospecimen core), a Radiology Center, a Pulmonary Function Test Reading Center, and a Sputum Reading Center. An Observational Studies Monitoring Board provides annual and ad hoc evaluations of the study with recommendations to the NHLBI. An External Scientific Board that is composed of representatives from the pharmaceutical industry and the US Food and Drug Administration serves in an advisory role.

DISCUSSION
The marked clinical and mechanistic heterogeneity that characterises COPD confounds development of novel treatments. It is likely that mechanistically based therapy will be effective only in selected subsets of the COPD population. SPIROMICS is designed to identify meaningful subsets of the COPD population appropriate for future mechanistically based therapeutic
interventions. Furthermore, the identification and validation of meaningful intermediate outcomes would facilitate development and testing of new treatments by enabling the design of more efficient clinical trials. Although a number of such measures have been suggested, the validation of these measures is limited by the lack of data in a well characterised, longitudinal COPD cohort.

Several other studies will complement SPIROMICS to help address these questions. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) used a 3-year observation period similar to SPIROMICS and shares similar goals. COPDGene was originally designed to explore the genetics of COPD in a large cohort of subjects. Longitudinal data and collection of blood biomarkers are now in progress.

While the goals for SPIROMICS are ambitious, there are limitations. Even combined with other large studies like COPDGene and ECLIPSE, SPIROMICS will not be able to fully characterise COPD heterogeneity, its natural history or to fully validate biomarkers and other intermediate outcomes. These goals will undoubtedly require additional studies. SPIROMICS is committed to sharing protocols, instruments and data with other investigators. The availability of standardised methods and datasets will facilitate the development of other large cohorts and expedite their comparison with SPIROMICS and other studies.

Strengths of SPIROMICS include the large cohort with two types of controls, detailed characterisation at baseline and longitudinally, and extensive follow-up, with central adjudication of intermediate outcomes.

In summary, SPIROMICS is a prospective observational study of COPD subjects and controls. It will characterise individuals with clinical, physiological, imaging, biochemical, cellular and histological parameters. Samples will be collected by a variety of methods. A subset of participants will be assessed at the time of an exacerbation. The characterisation of subjects with COPD will permit definition of meaningful subsets of patients with COPD. By assessing the relationship of clinical measures with longitudinal outcomes, SPIROMICS will advance validation of intermediate measures to be used in COPD. Finally, the availability of a well characterised cohort of participants that can be used in specific ancillary studies should prove to be a long-term resource for furthering understanding of COPD.

Author affiliations
1Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
2Division of Pulmonary & Critical Care, University of Michigan, Ann Arbor, Michigan, USA
3Department of Medicine, Columbia University, New York, New York, USA
4Center for Genomics and Personalized Medicine Research, Wake Forest University, Winston-Salem, New York, USA
5Department of Radiology, University of Iowa, Iowa City, Iowa, USA
6Department of Internal Medicine/Pulmonary and Critical Care Medicine, University of Utah, Salt Lake City, Utah, USA
7Department of Medicine, University of California at Los Angeles, Los Angeles, California, USA
8Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
9Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of California at San Francisco, San Francisco, California, USA
10Division of Pulmonary, Critical Care, Sleep & Allergy, Department of Internal Medicine, University of Nebraska, Omaha, Nebraska, USA

Collaborators
Neil Alexis, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Wayne Anderson, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Safwan Badr, Division of Pulmonary Critical Care and Sleep Medicine, Department of Internal Medicine, Wayne State University School of Medicine.


Chest clinic

Thorax: first published as 10.1136/thoraxjnl-2013-203897 on April 13, 2012 by guest. Protected by Copyright.

493
including service on speakers bureaus from Forest, Nycomed/Takeda, AstraZeneca, Bayer, William Beaumont Hospital, Boehringer Ingelheim, GSK, Lovelace, University of Illinois—Chicago, University of Texas—Southwestern, Wayne State University and Spectrum Health, royalties from Informa, payment for development of educational presentations from the American College of Chest Physicians, the Center for Healthcare Education, CME Incite, France Foundation, MedEd, NACE, St Luke’s Hospital, UpToDate, University of Virginia, American Thoracic Society, NCME, Projects in Knowledge, and MedScape/WebMD, service on a DSMB for Novartis. Wanda O’Neal reports salary support (other than for SPIROMICS) paid to her institution by the NIH. Robert Paine reports research grants (other than for SPIROMICS) from NHLBI and the Department of Veterans Affairs. Stephen P Peters reports service on advisory boards for AstraZeneca, Aerocrine, Airsonett AB, GlaxoSmithKline, Merck, Targacept and TEVA, payment for lectures from Merck, and Integrity Continuing Education, royalties from UpToDate. Stephen Rennard reports grants to his institution from AstraZeneca, Biomarck, Centocor, Mpex, Nabi, Novartis and Otsuka, consulting fees or honoraria from AstraZeneca, Novartis and Otsuka, board memberships for Almirall, Novartis, Nycomed and Pfizer, consultancies with Able Associates, Adelphi Research, API Pharma/Britnall, Avadigm, AstraZeneca, Chiesi, Commonwealth, Consult Complete, COPDForum, Data Monitor, Decision Resource, Defined Health, Dey, Dunn Group, Easton Associates, Equinox, Gerson, GlaxoSmithKline, Infomed, KOL Connextion, M. Pankove, MedaCorp, MDRx Financial, Mpex, Oriel Therapeutics, Otsuka, Pennside, ParmaVentures, Pharmaxis, Price Waterhouse, Propagate, Pulmatrix, Reckner Associates, Recruiting Resources, Roche, Schlesinger Medical, Scimed, Sudler and Hennessey, TargetGen, Therasave, UBC, Upstate Medical, VantagePoint Management, Forest, Nycomed, Pearl, Sankovy and Novartis, grants from AstraZeneca, Biomarck, Centocor, Mpex, Nabi, Novartis, Otsuka, Boehringer Ingelheim and Nycomed, payment for lectures including service on speakers bureaus from AAAAI, American College of Osteopathic Physicians, Asian Medical Center, American Thoracic Society, AstraZeneca, California Society of Allergy, Convergent Health Solutions for Reviews and Trends in COPD, COPDForum, Creative Educational Concepts, Dey, Duke University, France Foundation, Information TV, University of Southern California—Los Angeles, Network for Continuing Education (CHARM), Novartis (Horsham), Nycomed, Otsuka, Pfizer, Sarasota Memorial Hospital, Spanish Thoracic Society, University of Washington, University of Alabama—Birmingham, University of Pittsburgh, University of British Columbia, University of California—Davis, and Sioux Falls VA, travel, accommodation and meeting expenses, other than for SPIROMICS, from Amirall, AstraZeneca, Boehringer Ingelheim, California Allergy Society, Creative Educational Concept, France Foundation, GlaxoSmithKline, Information TV, Network for Continuing Education, Novartis, Nycomed and Pfizer. Krishna Sundar reports payment for lectures including service on speakers bureaus from Forest, and Boehringer Ingelheim, travel, accommodations and meeting expenses other than for SPIROMICS from Spiriva and Forest, serving as an investigator for Gilead. Donald P Taskin reports board memberships with Sunovion, AstraZeneka, Novartis and Mylan, consultancies with Sunovion, AstraZeneka, Novartis and Mylan, grants from Boehringer-Ingehelm, Pearl Therapeutics, Sunovion, GlaxoSmithKline, Forest and Pfizer, payment for lectures including service on speakers bureaus from Boehringer-Ingehelm, AstraZeneca, Forest, Novartis, Pfizer. Robert A Wise reports consultancies with BIPI, GSK, Merck, Mylan, Sunovion, Spiration, Pulmonx and Intermune, grants from BIPI, GSK and Merck. Prescott G Woodruff reports consultancies with Boehringer-Ingehelm, Merck, Kalobios and Medimmune. All other authors report only contracts/grants from NHLBI to their institution for SPIROMICS and for travel to SPIROMICS meetings.

Ethics approval The Institutional Research Board at each of the participating institutions.

Provenance and peer review Not commissioned; internally peer reviewed.

REFERENCES